Understanding the burden of interstitial lung disease post-COVID-19: the UK Interstitial Lung Disease-Long COVID Study (UKILD-Long COVID)
Open Access
- 23 September 2021
- journal article
- research article
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 8 (1), e001049
- https://doi.org/10.1136/bmjresp-2021-001049
Abstract
Introduction The COVID-19 pandemic has led to over 100 million cases worldwide. The UK has had over 4 million cases, 400 000 hospital admissions and 100 000 deaths. Many patients with COVID-19 suffer long-term symptoms, predominantly breathlessness and fatigue whether hospitalised or not. Early data suggest potentially severe long-term consequence of COVID-19 is development of long COVID-19-related interstitial lung disease (LC-ILD). Methods and analysis The UK Interstitial Lung Disease Consortium (UKILD) will undertake longitudinal observational studies of patients with suspected ILD following COVID-19. The primary objective is to determine ILD prevalence at 12 months following infection and whether clinically severe infection correlates with severity of ILD. Secondary objectives will determine the clinical, genetic, epigenetic and biochemical factors that determine the trajectory of recovery or progression of ILD. Data will be obtained through linkage to the Post-Hospitalisation COVID platform study and community studies. Additional substudies will conduct deep phenotyping. The Xenon MRI investigation of Alveolar dysfunction Substudy will conduct longitudinal xenon alveolar gas transfer and proton perfusion MRI. The POST COVID-19 interstitial lung DiseasE substudy will conduct clinically indicated bronchoalveolar lavage with matched whole blood sampling. Assessments include exploratory single cell RNA and lung microbiomics analysis, gene expression and epigenetic assessment. Ethics and dissemination All contributing studies have been granted appropriate ethical approvals. Results from this study will be disseminated through peer-reviewed journals. Conclusion This study will ensure the extent and consequences of LC-ILD are established and enable strategies to mitigate progression of LC-ILD.Funding Information
- Medical Research Council (MR/W006111/1)
This publication has 32 references indexed in Scilit:
- Covid-19: risk factors for severe disease and deathBMJ, 2020
- Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational studyThe Lancet Respiratory Medicine, 2020
- Airway Microstructure in Idiopathic Pulmonary Fibrosis: Assessment at Hyperpolarized 3He Diffusion-weighted MRIRadiology, 2019
- Hyperpolarised xenon magnetic resonance spectroscopy for the longitudinal assessment of changes in gas diffusion in IPFThorax, 2018
- Predicting Outcomes in Idiopathic Pulmonary Fibrosis Using Automated Computed Tomographic AnalysisAmerican Journal of Respiratory and Critical Care Medicine, 2018
- Peripheral endothelial function is positively associated with maximal aerobic capacity in patients with chronic obstructive pulmonary diseaseRespiratory Medicine, 2018
- 3D diffusion‐weighted 129Xe MRI for whole lung morphometryMagnetic Resonance in Medicine, 2017
- Host–Microbial Interactions in Idiopathic Pulmonary FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2017
- The Role of Bacteria in the Pathogenesis and Progression of Idiopathic Pulmonary FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2014
- Fleischner Society: Glossary of Terms for Thoracic ImagingRadiology, 2008